University of Jos Institutional Repository >
Medical Sciences >
Paediatrics >

Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/505

Title: Efficacy, Safety and Tolerability of Artesunate-mefloquine in the Treatment of Uncomplicated Plasmodium falciparum Malaria in Four Geographic Zones of Nigeria
Authors: Agomo, Philip .U
Meremikwu, Martin .M
Watila, Ismaila .M
Omalu, Innocent .J
Odey, Friday .A
Oguche, Stephen
Ezeiru, Valentine .I
Aina, Olugbenga .O
Issue Date: 9-Sep-2008
Publisher: Malaria Journal
Series/Report no.: Vol.7;No.172;Pp 1-9
Abstract: Background: The combination of artesunate and mefloquine has been reported to be effective against multidrug resistant Plasmodium falciparum malaria, which has been reported in Nigeria. The objective of this multicentre study was to evaluate the efficacy, safety and tolerability of the co-packaged formulation of artesunate and mefloquine in the treatment of uncomplicated malaria in two weight groups: those between 15 – 29 kg and ≥ 30 kg respectively. Methods: The trial was conducted in rural communities in the north-east, north-central, south-west and southeastern parts of Nigeria. The WHO protocol for testing antimalarial drugs was followed. Outpatients having amongst other criteria, parasite density of ≥1,000 μl were enrolled. The co-packaged drugs were administered for 3 days at a dosage of artesunate, 4 mg/kg body wt/day and mefloquine, 25 mg/kg/body wt total) on days 0, 1 and 2. Patients were followed up for 28 days with the assessment of the parasitological parameters on days 1, 2, 3, 7, and 28. Results: Four hundred and forty-six (446) patients were enrolled and 431 completed the study. Cure rates in both treatment groups was >90% at day 28. The mean parasite clearance times in treatment groups I and II were 40.1 and 42.4 hours respectively. The combination of artesunate and mefloquine showed good gametocidal activity, (gametocyte clearance time of 42.0 & 45.6 hours in treatment groups I and II respectively). There were no serious adverse events. Other adverse events observed were headache, dizziness, vomiting and abdominal discomfort. There was no significant derangement in the haematological and biochemical parameters. Conclusion: This co-packaged formulation of artesunate + mefloquine (Artequin™) is highly efficacious, safe and well-tolerated. It is recommended for the treatment of uncomplicated P. falciparum malaria in Nigeria.
URI: http://hdl.handle.net/123456789/505
Appears in Collections:Paediatrics

Files in This Item:

File Description SizeFormat
1475-2875-7-172.pdf559.3 kBAdobe PDFView/Open
View Statistics

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback